2023-02-012024-01-312024-01-31false11143155VETERINARY CARDIOLOGY SERVICES LIMITED2024-04-0582990iso4217:GBPxbrli:pure111431552023-02-01111431552024-01-31111431552023-02-012024-01-31111431552022-02-01111431552023-01-31111431552022-02-012023-01-3111143155bus:SmallEntities2023-02-012024-01-3111143155bus:AuditExempt-NoAccountantsReport2023-02-012024-01-3111143155bus:FullAccounts2023-02-012024-01-3111143155bus:PrivateLimitedCompanyLtd2023-02-012024-01-3111143155core:WithinOneYear2024-01-3111143155core:AfterOneYear2024-01-3111143155core:WithinOneYear2023-01-3111143155core:AfterOneYear2023-01-3111143155core:ShareCapital2024-01-3111143155core:SharePremium2024-01-3111143155core:RevaluationReserve2024-01-3111143155core:OtherReservesSubtotal2024-01-3111143155core:RetainedEarningsAccumulatedLosses2024-01-3111143155core:ShareCapital2023-01-3111143155core:SharePremium2023-01-3111143155core:RevaluationReserve2023-01-3111143155core:OtherReservesSubtotal2023-01-3111143155core:RetainedEarningsAccumulatedLosses2023-01-3111143155core:LandBuildings2024-01-3111143155core:PlantMachinery2024-01-3111143155core:Vehicles2024-01-3111143155core:FurnitureFittings2024-01-3111143155core:OfficeEquipment2024-01-3111143155core:NetGoodwill2024-01-3111143155core:IntangibleAssetsOtherThanGoodwill2024-01-3111143155core:ListedExchangeTraded2024-01-3111143155core:UnlistedNon-exchangeTraded2024-01-3111143155core:LandBuildings2023-01-3111143155core:PlantMachinery2023-01-3111143155core:Vehicles2023-01-3111143155core:FurnitureFittings2023-01-3111143155core:OfficeEquipment2023-01-3111143155core:NetGoodwill2023-01-3111143155core:IntangibleAssetsOtherThanGoodwill2023-01-3111143155core:ListedExchangeTraded2023-01-3111143155core:UnlistedNon-exchangeTraded2023-01-3111143155core:LandBuildings2023-02-012024-01-3111143155core:PlantMachinery2023-02-012024-01-3111143155core:Vehicles2023-02-012024-01-3111143155core:FurnitureFittings2023-02-012024-01-3111143155core:OfficeEquipment2023-02-012024-01-3111143155core:NetGoodwill2023-02-012024-01-3111143155core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3111143155core:ListedExchangeTraded2023-02-012024-01-3111143155core:UnlistedNon-exchangeTraded2023-02-012024-01-3111143155core:MoreThanFiveYears2023-02-012024-01-3111143155core:Non-currentFinancialInstruments2024-01-3111143155core:Non-currentFinancialInstruments2023-01-3111143155dpl:CostSales2023-02-012024-01-3111143155dpl:DistributionCosts2023-02-012024-01-3111143155core:LandBuildings2023-02-012024-01-3111143155core:PlantMachinery2023-02-012024-01-3111143155core:Vehicles2023-02-012024-01-3111143155core:FurnitureFittings2023-02-012024-01-3111143155core:OfficeEquipment2023-02-012024-01-3111143155dpl:AdministrativeExpenses2023-02-012024-01-3111143155core:NetGoodwill2023-02-012024-01-3111143155core:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3111143155dpl:GroupUndertakings2023-02-012024-01-3111143155dpl:ParticipatingInterests2023-02-012024-01-3111143155dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-012024-01-3111143155core:ListedExchangeTraded2023-02-012024-01-3111143155dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-012024-01-3111143155core:UnlistedNon-exchangeTraded2023-02-012024-01-3111143155dpl:CostSales2022-02-012023-01-3111143155dpl:DistributionCosts2022-02-012023-01-3111143155core:LandBuildings2022-02-012023-01-3111143155core:PlantMachinery2022-02-012023-01-3111143155core:Vehicles2022-02-012023-01-3111143155core:FurnitureFittings2022-02-012023-01-3111143155core:OfficeEquipment2022-02-012023-01-3111143155dpl:AdministrativeExpenses2022-02-012023-01-3111143155core:NetGoodwill2022-02-012023-01-3111143155core:IntangibleAssetsOtherThanGoodwill2022-02-012023-01-3111143155dpl:GroupUndertakings2022-02-012023-01-3111143155dpl:ParticipatingInterests2022-02-012023-01-3111143155dpl:GroupUndertakingscore:ListedExchangeTraded2022-02-012023-01-3111143155core:ListedExchangeTraded2022-02-012023-01-3111143155dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-02-012023-01-3111143155core:UnlistedNon-exchangeTraded2022-02-012023-01-3111143155core:NetGoodwill2024-01-3111143155core:IntangibleAssetsOtherThanGoodwill2024-01-3111143155core:LandBuildings2024-01-3111143155core:PlantMachinery2024-01-3111143155core:Vehicles2024-01-3111143155core:FurnitureFittings2024-01-3111143155core:OfficeEquipment2024-01-3111143155core:AfterOneYear2024-01-3111143155core:WithinOneYear2024-01-3111143155core:ListedExchangeTraded2024-01-3111143155core:UnlistedNon-exchangeTraded2024-01-3111143155core:ShareCapital2024-01-3111143155core:SharePremium2024-01-3111143155core:RevaluationReserve2024-01-3111143155core:OtherReservesSubtotal2024-01-3111143155core:RetainedEarningsAccumulatedLosses2024-01-3111143155core:NetGoodwill2023-01-3111143155core:IntangibleAssetsOtherThanGoodwill2023-01-3111143155core:LandBuildings2023-01-3111143155core:PlantMachinery2023-01-3111143155core:Vehicles2023-01-3111143155core:FurnitureFittings2023-01-3111143155core:OfficeEquipment2023-01-3111143155core:AfterOneYear2023-01-3111143155core:WithinOneYear2023-01-3111143155core:ListedExchangeTraded2023-01-3111143155core:UnlistedNon-exchangeTraded2023-01-3111143155core:ShareCapital2023-01-3111143155core:SharePremium2023-01-3111143155core:RevaluationReserve2023-01-3111143155core:OtherReservesSubtotal2023-01-3111143155core:RetainedEarningsAccumulatedLosses2023-01-3111143155core:NetGoodwill2022-02-0111143155core:IntangibleAssetsOtherThanGoodwill2022-02-0111143155core:LandBuildings2022-02-0111143155core:PlantMachinery2022-02-0111143155core:Vehicles2022-02-0111143155core:FurnitureFittings2022-02-0111143155core:OfficeEquipment2022-02-0111143155core:AfterOneYear2022-02-0111143155core:WithinOneYear2022-02-0111143155core:ListedExchangeTraded2022-02-0111143155core:UnlistedNon-exchangeTraded2022-02-0111143155core:ShareCapital2022-02-0111143155core:SharePremium2022-02-0111143155core:RevaluationReserve2022-02-0111143155core:OtherReservesSubtotal2022-02-0111143155core:RetainedEarningsAccumulatedLosses2022-02-0111143155core:AfterOneYear2023-02-012024-01-3111143155core:WithinOneYear2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:CostValuation2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-012024-01-3111143155core:Non-currentFinancialInstrumentscore:CostValuation2024-01-3111143155core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-01-3111143155core:Non-currentFinancialInstrumentscore:CostValuation2023-01-3111143155core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-3111143155core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-3111143155core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-3111143155core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-3111143155core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-3111143155core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-3111143155core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-3111143155core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-3111143155bus:Director12023-02-012024-01-3111143155bus:Director22023-02-012024-01-31

VETERINARY CARDIOLOGY SERVICES LIMITED

Registered Number
11143155
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2024

VETERINARY CARDIOLOGY SERVICES LIMITED
Company Information
for the year from 1 February 2023 to 31 January 2024

Directors

BROWN, Laurence John
CATANI-BROWN, Claudia Maria

Company Secretary

CATANI-BROWN, Claudia Maria

Registered Address

Red House Main Street
Osgodby
Market Rasen
LN8 3PA

Registered Number

11143155 (England and Wales)
VETERINARY CARDIOLOGY SERVICES LIMITED
Balance Sheet as at
31 January 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets320,73025,293
20,73025,293
Current assets
Debtors14,8271,260
Cash at bank and on hand47,11190,053
61,93891,313
Creditors amounts falling due within one year4(11,347)(75,664)
Net current assets (liabilities)50,59115,649
Total assets less current liabilities71,32140,942
Provisions for liabilities5-(4,806)
Net assets71,32136,136
Capital and reserves
Called up share capital1010
Profit and loss account71,31136,126
Shareholders' funds71,32136,136
The financial statements were approved and authorised for issue by the Board of Directors on 5 April 2024, and are signed on its behalf by:
BROWN, Laurence John
Director
Registered Company No. 11143155
VETERINARY CARDIOLOGY SERVICES LIMITED
Notes to the Financial Statements
for the year ended 31 January 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Turnover from the sale of goods is recognised when significant risks and rewards of ownership of the goods have transferred to the buyer, the amount of turnover can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
Employee benefits
When employees have rendered service to the company, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service. The company operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.
Foreign currency translation
Foreign currency transactions are initially recognised by applying to the foreign currency amount the spot exchange rate between the functional currency and the foreign currency at the date of the transaction. Monetary assets and liabilities denominated in a foreign currency at the balance sheet date are translated using the closing rate.
Deferred tax
Deferred tax represents the future tax consequences of transactions and events recognised in the financial statements of current and previous periods. It is recognised in respect of all timing differences, with certain exceptions. Timing differences are differences between taxable profits and total comprehensive income as stated in the financial statements that arise from the inclusion of income and expense in tax assessments in periods different from those in which they are recognised in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date that are expected to apply to the reversal of timing differences. Deferred tax on revalued non-depreciable tangible fixed assets and investment properties is measured using the rates and allowances that apply to the sale of the asset.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life as follows:

Reducing balance (%)Straight line (years)
Plant and machinery15-
Vehicles25-
Office Equipment-33.3
2.Average number of employees

20242023
Average number of employees during the year22
3.Tangible fixed assets

Plant & machinery

Vehicles

Office Equipment

Total

££££
Cost or valuation
At 01 February 2333,73032,39549966,624
At 31 January 2433,73032,39549966,624
Depreciation and impairment
At 01 February 2316,12324,70850041,331
Charge for year2,6411,922-4,563
At 31 January 2418,76426,63050045,894
Net book value
At 31 January 2414,9665,765(1)20,730
At 31 January 2317,6077,687(1)25,293
4.Creditors: amounts due within one year

2024

2023

££
Taxation and social security9,9076,044
Other creditors-67,566
Accrued liabilities and deferred income1,4402,054
Total11,34775,664
Creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment.
5.Provisions for liabilities

2024

2023

££
Net deferred tax liability (asset)-4,806
Total-4,806